Hannah Lentschat

Hannah Lentschat

Auto-generated profile, based on publicly available information

Hannah Lentschat

Institute of Biochemistry Faculty of Life Sciences Leipzig University Leipzig 04103 Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
HLHannah Lentschat
Hannah Lentschat
FLFabian Liessmann
Fabian Liessmann
CTClaiborne Tydings
Claiborne Tydings
TSTina Schermeng
Tina Schermeng
JSJan Stichel
Jan Stichel
ABAnnette Beck-Sickinger
Annette Beck-Sickinger
RF‐amide peptide receptors including the neuropeptide FF receptor 1 (NPFFR1) are G protein‐coupled receptors (GPCRs) that modulate diverse physiological functions. High conservation of endogenous ligands and receptors makes the identification of selective ligands challenging. Previously identified antagonists mimic the C‐terminus of peptide ligands and lack selectivity towards the closely related neuropeptide FF receptor 2 (NPFFR2) or the neuropeptide Y1 receptor (Y1R). In a high‐throughput screening, we identified the pentacyclic triterpenoid hederagenin (1) as a novel selective antagonist for the NPFFR1. Hederagenin (1) is a natural product isolated from Hedera helix (ivy). We characterized its mode of activity using in vitro and in silico methods, revealing an overlapping binding site of the small molecule with the orthosteric peptide agonists. Despite the high similarity of the orthosteric binding pockets of NPFFR1 and NPFFR2, hederagenin (1) shows strong subtype selectivity, particularly caused by slight differences in the shape of the binding pockets and the rigidity of the small molecule. Several residues inhibiting the activity of hederagenin (1) at the NPFFR2 were identified. As NPFFR1 antagonists are discussed as potential candidates for the treatment of chronic pain, these insights into the structural determinants governing subtype specificity will facilitate the development of next‐generation analgesics with improved safety and efficacy.

9 December 2024 in Angewandte Chemie
Verified
Journal Article
Open access
HLHannah Lentschat
Hannah Lentschat
FLFabian Liessmann
Fabian Liessmann
CTClaiborne Tydings
Claiborne Tydings
TSTina Schermeng
Tina Schermeng
JSJan Stichel
Jan Stichel
ABAnnette Beck-Sickinger
Annette Beck-Sickinger
RF‐amide peptide receptors including the neuropeptide FF receptor 1 (NPFFR1) are G protein‐coupled receptors (GPCRs) that modulate diverse physiological functions. High conservation of endogenous ligands and receptors makes the identification of selective ligands challenging. Previously identified antagonists mimic the C‐terminus of peptide ligands and lack selectivity towards the closely related neuropeptide FF receptor 2 (NPFFR2) or the neuropeptide Y1 receptor (Y1R). In a high‐throughput screening, we identified the pentacyclic triterpenoid hederagenin (1) as a novel selective antagonist for the NPFFR1. Hederagenin (1) is a natural product isolated from Hedera helix (ivy). We characterized its mode of activity using in vitro and in silico methods, revealing an overlapping binding site of the small molecule with the orthosteric peptide agonists. Despite the high similarity of the orthosteric binding pockets of NPFFR1 and NPFFR2, hederagenin (1) shows strong subtype selectivity, particularly caused by slight differences in the shape of the binding pockets and the rigidity of the small molecule. Several residues inhibiting the activity of hederagenin (1) at the NPFFR2 were identified. As NPFFR1 antagonists are discussed as potential candidates for the treatment of chronic pain, these insights into the structural determinants governing subtype specificity will facilitate the development of next‐generation analgesics with improved safety and efficacy.

20 May 2026 in RSC Advances
Verified
Journal Article
Open access
PDF file
HLHannah Lentschat
Hannah Lentschat
ABAnnette Beck-Sickinger
Annette Beck-Sickinger
Characterization of ligand binding at the neuropeptide FF receptor 1 (NPFFR1) through a nanoBRET-based assay.